Literature DB >> 16391791

Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.

Xiaodong Tan1, Hiroshi Egami, Fumiaki Nozawa, Michio Abe, Hideo Baba.   

Abstract

To clarify the potential involvement of plasmin(ogen) cascade proteins in the cell dissociation and subsequent invasion of pancreatic cancer cells, western blot analysis, immunocytochemistry, immunohistochemistry, and in vitro invasion assay were performed in the cell lines or tissue of pancreatic cancer. The strong expression of plasmin(ogen), urokinase type plasminogen activator (uPA) and uPA receptor (uPAR), and apparently weak expression of the relevant proteins were found in the conditioned medium of dissociated (PC-1.0) and non-dissociated (PC-1) pancreatic cancer cells, respectively. Furthermore, uPA-treatment significantly induced the expression of plasmin(ogen) and uPAR in the conditioned medium of non-dissociated (PC-1) pancreatic cancer cells. Moreover, the expression of plasmin(ogen) and uPAR was stronger at the invasive front than at the center of human pancreatic cancer tissue. On the other hand, plasmin-treatment induced the expression of matrix metalloproteinase-2 (MMP-2), MMP-7 and MMP-9 in PC-1 cells. Simultaneously, plasmin- or uPA-treatments obviously induced the dissociation of cell colonies and in vitro invasiveness in PC-1 cells. The plasmin(ogen) cascade is closely involved in the invasion of pancreatic cancer cells and, especially in its early stage, cell dissociation. Targeting the plasmin(ogen) cascade may provide a new insight into molecular target therapy based on anti-invasion and anti-metastasis for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391791

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  20 in total

Review 1.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

Review 2.  Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis.

Authors:  Chen Huang; Keping Xie
Journal:  Cytokine Growth Factor Rev       Date:  2012-02-16       Impact factor: 7.638

3.  Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells.

Authors:  Anja Elstner; Nikola Holtkamp; Andreas von Deimling
Journal:  Clin Exp Metastasis       Date:  2007-03-15       Impact factor: 5.150

4.  Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.

Authors:  Lily Yang; Hui Mao; Zehong Cao; Y Andrew Wang; Xianghong Peng; Xiaoxia Wang; Hari K Sajja; Liya Wang; Hongwei Duan; Chunchun Ni; Charles A Staley; William C Wood; Xiaohu Gao; Shuming Nie
Journal:  Gastroenterology       Date:  2009-01-14       Impact factor: 22.682

5.  Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.

Authors:  Gee Young Lee; Wei Ping Qian; Liya Wang; Yongqiang Andrew Wang; Charles A Staley; Minati Satpathy; Shuming Nie; Hui Mao; Lily Yang
Journal:  ACS Nano       Date:  2013-03-12       Impact factor: 15.881

6.  Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.

Authors:  Meritxell Huch; Alena Gros; Anabel José; Juan Ramon González; Ramon Alemany; Cristina Fillat
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

7.  IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.

Authors:  Hongyu Zhou; Weiping Qian; Fatih M Uckun; Liya Wang; Y Andrew Wang; Hongyu Chen; David Kooby; Qian Yu; Malgorzata Lipowska; Charles A Staley; Hui Mao; Lily Yang
Journal:  ACS Nano       Date:  2015-08-10       Impact factor: 15.881

8.  Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor.

Authors:  Naveen R Palwai; Xiao-Ping Zang; Roger G Harrison; Doris Benbrook; J Thomas Pento
Journal:  Pharmacology       Date:  2009-10-01       Impact factor: 2.547

9.  RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.

Authors:  Padmaja Tummalapalli; Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-07       Impact factor: 5.650

10.  Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.

Authors:  Natasa Obermajer; Bojan Doljak; Janko Kos
Journal:  Mol Cancer       Date:  2009-10-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.